The Fachkrankenhaus Coswig hospital is a clinic specializing in the treatment of bronchial and pulmonary diseases. In 2018, a total of approx. 8,000 patients were treated in the FKC hospital which has 171 beds.

During the past decade, Fachkrankenhaus Coswig GmbH conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 10 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fachkrankenhaus Coswig GmbH" #1 sponsor was "Boehringer Ingelheim" with 8 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "ResMed" with 2 trials sponsored, "CSL Behring" with 1 trials sponsored and "Galapagos NV" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fachkrankenhaus Coswig GmbH" #1 collaborator was "CAPNETZ Stiftung" with 1 trials as a collaborator, "CRI-The Clinical Research Institute GmbH" with 1 trials as a collaborator, "European Society of Anaesthesiology and Intensive Care" with 1 trials as a collaborator, "German Center for Lung Research" with 1 trials as a collaborator and "InterMune Deutschland GmbH" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Fachkrankenhaus Coswig GmbH" are "Idiopathic Pulmonary Fibrosis" (10 trials), "Lung Diseases, Interstitial" (4 trials), "Non-Small Cell Lung Cancer" (2 trials), "Bronchiectasis" (1 trials) and "Congestive Heart Failure" (1 trials). Many other conditions were trialed in "Fachkrankenhaus Coswig GmbH" in a lesser frequency.

Most popular intervention types in "Fachkrankenhaus Coswig GmbH" are "Drug" (17 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Nintedanib" (5 trials), "Pirfenidone" (4 trials), "BI 1015550" (3 trials) and "Erlotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Fachkrankenhaus Coswig GmbH" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Fachkrankenhaus Coswig GmbH". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Fachkrankenhaus Coswig GmbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Fachkrankenhaus Coswig GmbH, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".